Updates in the Treatment of HR+ Breast Cancer : Episode 6
Opinion
Video
Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer
A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.
EP: 1.Expert Insights on Biomarker Testing in Early-Stage Breast Cancer
EP: 2.Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer
EP: 3.Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer
EP: 4.Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer
EP: 5.Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA
Now Viewing
EP: 6.Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer
EP: 7.Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer
EP: 8.Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant
EP: 9.Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer
EP: 10.ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06
EP: 11.Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer
EP: 12.Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape
Video content above is prompted by the following:
- What are the CDK4/6i options?
- Please briefly review the main clinical trials and recent data.
- How do the data for the 3 CDK4/6i compare?
Related Videos
Related Content
